Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Safety and Tolerability Study of Tozadenant Added to Levodopa in Parkinson's Disease with End-of-Dose Wearing-Off
2016-003961-25Phase 3Terminated
- Sponsor
- Biotie Therapies
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tozadenant in Parkinson's disease (PD), sponsored by Biotie Therapies. Primary endpoint: Treatment-emergent adverse events. Started Feb 2017; status: terminated.
02
Drugs
tozadenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2016-003961-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003961-25.